Arcus Biosciences (RCUS) Non-Current Deffered Revenue (2017 - 2026)

Arcus Biosciences' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $45.0 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 79.45% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at $45.0 million (down 79.45% YoY), while the FY2025 annual figure was $43.0 million, down 81.62% from the prior year.
• Non-Current Deffered Revenue was $45.0 million for Q1 2026 at Arcus Biosciences, up from $43.0 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $456.9 million in Q1 2022 to a low of $43.0 million in Q4 2025.
• Historically, Non-Current Deffered Revenue has averaged $253.9 million across 5 years, with a median of $289.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue surged 313.19% in 2022, then tumbled 81.66% in 2025.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $355.0 million in 2022, then declined by 13.52% to $307.0 million in 2023, then declined by 23.78% to $234.0 million in 2024, then plunged by 81.62% to $43.0 million in 2025, then increased by 4.65% to $45.0 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $45.0 million (Q1 2026), $43.0 million (Q4 2025), and $53.0 million (Q3 2025), per Business Quant data.